Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

被引:74
作者
Rafati, S
Zahedifard, F
Nazgouee, F
机构
[1] Inst Pasteur, Mol Immunol & Vaccine Res Lab, Tehran, Iran
[2] Inst Pasteur, Clin Res Unit, Tehran, Iran
关键词
cysteine proteinase type I and II; prime-boost vaccination; Leishmania infantum;
D O I
10.1016/j.vaccine.2005.11.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination with a cocktail of DNA encoding cysteine proteinases has been previously shown to confer protection against experimental cutaneous leishmaniasis (CL). In the present study we test the efficacy of immunization against Leishmania infantum in a murine model of infection, using a prime-boost strategy. BALB/c mice were immunized twice, in a 3 weeks interval, with cocktail of plasmids DNA encoding type I (cpb) and II (cpa) cysteine proteinases. DNA immunization was then followed by a boost with rCPA/rCPB in addition to CpG ODN and Montanide720 as adjuvant. Analysis of the immune response showed that vaccination mainly elicited antigen-specific IgG2a antibodies, suggesting the induction of a Th1 immune response. This was further confirmed by the analysis of the splenic cytokine production: at all time points the ratio of IFN-gamma/IL-5 induced upon restimulation with rCPA and rCPB was always significantly higher in vaccinated group compared to both control groups. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2169 / 2175
页数:7
相关论文
共 33 条
[21]   Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis [J].
Rafati, S ;
Nakhaee, A ;
Taheri, T ;
Ghashghaii, A ;
Salmanian, AH ;
Jimenez, M ;
Mohebali, M ;
Masina, S ;
Fasel, N .
EXPERIMENTAL PARASITOLOGY, 2003, 103 (3-4) :143-151
[22]   Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice:: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation [J].
Rafati, S ;
Kariminia, A ;
Seyde-Eslami, S ;
Narimani, M ;
Taheri, T ;
Lebbatard, M .
VACCINE, 2002, 20 (19-20) :2439-2447
[23]   A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major [J].
Rafati, S ;
Salmanian, AH ;
Taheri, T ;
Vafa, M ;
Fasel, N .
VACCINE, 2001, 19 (25-26) :3369-3375
[24]  
RAFATI S, 2003, CURR GENOMICS, V4, P109
[25]   Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection [J].
Rhee, EG ;
Mendez, S ;
Shah, JA ;
Wu, CY ;
Kirman, JR ;
Turon, TN ;
Davey, DF ;
Davis, H ;
Klinman, DM ;
Coler, RN ;
Sacks, DL ;
Seder, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1565-1573
[26]   Visceral leishmaniasis in those infected with HIV:: clinical aspects and other opportunistic infections [J].
Russo, R ;
Laguna, F ;
López-Vélez, R ;
Medrano, FJ ;
Rosenthal, E ;
Cacopardo, B ;
Nigro, L .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2003, 97 :99-105
[27]   The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: Course and impact from 1984 to 1994 [J].
Seaman, J ;
Mercer, AJ ;
Sondorp, E .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1996, 25 (04) :862-871
[28]  
Solbach W, 2000, Adv Immunol, V74, P275, DOI 10.1016/S0065-2776(08)60912-8
[29]   Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major [J].
Stacey, KJ ;
Blackwell, JM .
INFECTION AND IMMUNITY, 1999, 67 (08) :3719-3726
[30]   Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis [J].
Stäger, S ;
Smith, DF ;
Kaye, PM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :7064-7071